A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis
Small · 2026
DOI: 10.1002/smll.202511555 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2026. Verfasst von Anwesha Mukherjee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, Punjab, India. Hauptthemen laut MEDLINE: Quercetin, Osteoarthritis, Mesenchymal Stem Cells, Nanoparticles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: DBT, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Osteoarthritis (OA) is a progressive, chronic disorder of the musculoskeletal system affecting more than 500 million individuals globally. Current treatment strategies primarily provide palliative care, with limited potential to alter disease progression or reverse tissue deterioration. Stem cell transplantation holds promising results. But poor cell retention and survival due to ROS and inflammation in OA lead to subpar therapeutic outcomes. In this study, we developed a dual‐network gelatin methacrylate (GelMA) and κ‐carrageenan‐based injectable hydrogel loaded with antioxidant quercetin‐PLGA nanoparticles for stem cell delivery to treat OA. Physicochemical studies demonstrated stable gelation, controlled degradation, and self‐healing properties. In vitro studies revealed that the sustained release of quercetin effectively scavenged intracellular ROS, reduced the expression of pro‐inflammatory factors such as IL6, COX2, NFκβ, and TNFα, and increased the expression of TGFβ, IL4, SOX9, COL2, and ACAN, which are responsible for inflammation control and cartilage tissue regeneration. The sustained release of nanoparticles also enhanced the M1‐to‐M2 macrophage transition and collagen II deposition. In vivo studies demonstrated that the nanoparticle‐loaded stem cell‐encapsulated hydrogel increased glycosaminoglycan deposition, reduced inflammation, and improved joint mobility and cartilage repair. Thus, this antioxidant hydrogel‐based cell delivery system demonstrated suitability for OA therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, Punjab, India.
- School of Interdisciplinary Research, Indian Institute of Technology Delhi, New Delhi, India.
- Chandigarh College of Pharmacy, Landran, Mohali, India.
- Department of Mechanical Engineering, Indian Institute of Technology Delhi, New Delhi, India.
ORCID-Profile: Anwesha Mukherjee, Saswata Mitra, Nilangshuk Chaudhuri, Rupinder K Sodhi, Kaushik Mukherjee, Bodhisatwa Das
Förderung
- DBT
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Mukherjee, A., Mitra, S., Chaudhuri, N., Sodhi, R. K., Mukherjee, K., & Das, B. (2026). A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis. Small. https://doi.org/10.1002/smll.202511555
Vancouver
Mukherjee A, Mitra S, Chaudhuri N, Sodhi RK, Mukherjee K, Das B. A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis. Small. 2026. doi:10.1002/smll.202511555
BibTeX
@article{Mukherjee2026,
author = {Mukherjee, Anwesha and Mitra, Saswata and Chaudhuri, Nilangshuk and Sodhi, Rupinder K and Mukherjee, Kaushik and Das, Bodhisatwa},
title = {A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis},
journal = {Small},
year = {2026},
doi = {10.1002/smll.202511555}
}
EUVIMED